|Bid||0.0256 x 0|
|Ask||0.0440 x 0|
|Day's Range||0.0258 - 0.0258|
|52 Week Range||0.0060 - 0.0890|
|Beta (5Y Monthly)||3.14|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In addition, the Company conducted 2,130 physician-patient consultations setting a new historic milestone in patient volume for the month of June. Additionally, to the knowledge of the Company, there have been no material business developments as of the date of this news release that have not been generally disclosed.
Empower to open wellness clinic in Vancouver, B.C. to support the development of the psychedelics division Dosed Wellness and to establish Canadian headquarters for Empower Clinics Inc. The Company also confirms significant progress has been made with negotiations on the definitive agreement related to the previously announced non-binding term sheet with Golden Teacher Films Inc. ("Golden"), to acquire a 10% interest in certain royalty rights, intellectual property rights and interest in Dosed Movie ("DOSED"), an award-wining documentary film about treating anxiety, depression and addiction with psychedelic medicine.
The Webinar is titled: "Psychedelic Stocks On The Charge in North America Creates Opportunities for Global Investors" and is being hosted by Peter Hunt, Co-founder and Chair of Mind Medicine Australia. "Having the opportunity to participate in the Peak Asset Management's Psychedelics Webinar in front of a diverse international audience, allows me to advocate for the impact psychedelic treatments may have for global mental health issues."
In addition, the Company, in its Portland clinic is successfully collecting signatures for the IP34 ballot for the psilocybin therapy initiative. The YES on the IP34 ballot initiative in Oregon has written that psilocybin-assisted therapy is different than the current mental health system; the focus is on treatment and health that doesn't depend on a lifetime of pills.
Empower has commenced phase three of COVID-19 testing with a successful pilot of business employee testing and outperforms expected May 2020 patient volume with over 2,300 physician-patient consultations. In addition, the Company conducted 2,302 physician-patient consultations setting a new milestone in patient volume for the month of May. "We established a four-phase approach to the roll-out of COVID-19 testing, ensuring operational excellence throughout the launch", said Steven McAuley, Chairman & CEO of Empower.
VANCOUVER, BC / ACCESSWIRE / May 27th, 2020 / EMPOWER CLINICS INC. (CBDT.CN) (EPWCF) (Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated life sciences company, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 the Company is forming a global mushroom education initiative with EuroLife Brands ("EuroLife") that will leverage the cannvas.me platform. The new initiative expands the original agreement by formalizing a cloud-based, globally accessible, leading educational experience for patients, clinics, and academic circles to participate, learn, interact, and create information on the uses, treatments, and applications of mushrooms for health and wellness. The global initiative will be positioned as an educational platform but will also accept clinical trial results, integrate with universities and academic circles, provide knowledge and a safe learning experience free from the outside influence of misinformation.
EuroLife's Enterprise Learning Platforms to power Empower's online education for over 165,000 patients on the potential benefits of mushrooms and their potential impact on health and wellness Toronto, Ontario--(Newsfile Corp. - May 26, 2020) - EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTC PINK: EURPF) ("EuroLife" or the "Company"), a vertically integrated enterprise focused on the pan-European health and wellness sector, is pleased to announce that further to the definitive agreement announced on May 15th, 2020 ...
Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie, launches Dosed Wellness, a psychedelics brand, launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand. Under the terms of the agreement, the Company intends to issue $75,000.00 CAD of common shares in the capital of Empower (each, a "Share") plus an aggregate payment of $25,000.00 CAD to the Vendors at the Closing. Further, the principals of Golden, Tyler Chandler and Nicholas Meyers will be offered consulting contracts to join the management team of Dosed Wellness Ltd.
VANCOUVER, BC / ACCESSWIRE / May 15th, 2020 / EMPOWER CLINICS INC. (CBDT.CN) (EPWCF) (Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated life sciences company, is pleased to announce that further to the letter of intent announced on February 25, 2020 it has signed a definitive agreement with EuroLife Brands ("EuroLife"), a vertically integrated enterprise focused on the pan-European hemp, cannabinoid, and health and wellness sector. The agreement grants Empower an exclusive license to EuroLife's "Cannvas.me" cloud based online educational platform in certain international jurisdictions. Empower will use the web-based education technology platform to deliver brand, product, and industry knowledge to employees and over 165,000 patients across Empower's six corporate clinics in Arizona, Oregon, its first franchise in Oklahoma and nationwide tele-health platform.
The Company is booking new physician appointments for immune boosting services that are leading to naturopathic product sales and the ordering of specialized tests. In addition, the Company has increased orders of Personal Protective Equipment (PPE) and equipment such as stainless-steel tables, portable air conditioning units, tents and medical supplies to support staff and patients as part of a medical testing protocol in the United States. The Company has also been identified by Amazon Business as needing access to critical supplies and as such, the Company has been awarded access to the Amazon COVID-19 SUPPLIES portal, which provides access to essential products for organizations participating in the fight against Coronavirus.
Empower confirms it has commenced COVID-19 antibody testing in clinics under the phase one and phase two rollout plans, receives first Rapid COVID-19 test kits and places additional purchases of Rapid COVID-19 test kits. The Company has also received its first Rapid COVID-19 antibody test kits and has purchased additional Rapid test kits to start meeting testing demand. The Company also provides an update on the timing of the release of its financial results and associated filings for the fourth quarter and fiscal year ended December 31, 2019.
Empower is utilizing clinic operations and tele-medicine to provide COVID-19 antibody testing to patients and consumers, establishes a four-phase nationwide rollout of Rapid COVID-19 testing and signs new COVID-19 test supply agreements. "The Company has established a four-phase national COVID-19 testing program utilizing Rapid COVID-19 test kits", said Steven McAuley, Chairman & CEO of Empower. Phase One Testing in-clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours.
VANCOUVER, BC / ACCESSWIRE / April 22, 2020 / EMPOWER CLINICS INC. (CBDT.CN)(EPWCF)(Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated and growth-oriented life sciences company is pleased to announce, it is has created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder (PTSD) and addiction. The Company is leveraging its assets that include the existing clinic network, the developing franchise brand, tele-medicine, access to its 165,000 patients and large physician team, to make advancements in psilocybin research and psychedelics therapy in general. "Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic."
The proceeds of the Offering are expected to be used by the Company for general working capital and corporate purposes. The Company, as part of the recently announced digital health initiative, has added physician based tele-medicine consultations to address immune system boosting requirements for existing patients and new patients, on a nationwide basis. The Company clinics have also seen a 480% increase in patient visits in the first half of April 2020.
VANCOUVER, BC / ACCESSWIRE / April 1, 2020 / EMPOWER CLINICS INC. (CBDT.CN) (EPWCF) (Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated and growth-oriented life sciences company, is pleased to announce that patient visits in corporate clinics increased by 593%% in March 2020 versus the same period in 2019, with total patient visits of 2,160 in March 2020 compared to 364 in March 2019. 1Q 2020 patient visits increased by 478% versus the same period 2019, with total patient visits of 5,717 in 1Q 2020 compared to 1,196 in 1Q 2019. "These are unprecedented times, yet our team members remain dedicated to supporting patients every day, at record levels, using new operational techniques and safety protocols" said Steven McAuley, Chairman & CEO of Empower.
VANCOUVER, BC / ACCESSWIRE / March 4, 2020 / EMPOWER CLINICS INC. (CBDT.CN) (EPWCF) (Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated and growth-oriented life sciences company, is pleased to announce that patient visits in corporate clinics increased by 800% in February 2020 versus the same period in 2019, with total patient visits of 1,817 in February 2020 compared to 227 in February 2019. The Company also has received numerous inquiries with both positive and supportive sentiment, after the recent announcement of the Company's intention to create a psilocybin and psychedelics division. "Getting positive reinforcement from researchers, physicians, advocates and practitioners about our intention to enter this developing field of study, gives me confidence that we have made the correct decision to leverage our corporate assets for psilocybin and psychedelics research and development."
The Company has been conducting market research on advancements in psilocybin and psychedelics in North America and globally, along with building the business case internally on how to create greater shareholder value, utilizing Company assets that include clinics, patients, physicians and technology. "There is an undeniable mental health crisis in our country and around the world, that has an ever-increasing, devastating affect on our society." said Steven McAuley, Chairman & CEO of Empower.
VANCOUVER BC / ACCESSWIRE / February 19, 2020 / EMPOWER CLINICS INC. (CBDT.CN) (EPWCF) (Frankfurt 8EC) ("Empower" or the "Company"), a vertically integrated and growth-oriented CBD life sciences company is pleased to announce it has launched a series of re-formulated versions of it's CBD tincture product line SOLLIEVO. The new formulated Sollievo is non-GMO, non-psychoactive, has rapid bioavailability and is sourced from USA grown hemp.
Empower Clinics to license online education technology to provide strategic value to their patients, retail locations, and to their expanding network of franchisees. The education technology is to be accessed by employees of Empower's owned and franchised clinics, patients, and a network of nationwide retailers in the United States. Under the terms of the LOI, Empower will be granted an exclusive license of the Cannvas.me platform in the United States and Mexico (expandable to other jurisdictions).
Empower Clinics to license online education technology to provide strategic value to their patients, retail locations, and to their expanding network of franchisees. Toronto, Ontario--(Newsfile Corp. - February 13, 2020) - EuroLife Brands (CSE: EURO) (FSE: 3CMA) (OTC Pink: EURPF) ("EuroLife" or the "Company"), a vertically integrated enterprise focused on the pan-European hemp, cannabinoid, and health and wellness sector, is pleased to announce it has signed a letter of intent (the "LOI") with Empower Clinics ...
In addition, the Company will run an onsite Sun Valley Health POP-UP medical clinic, offering cannabis consultations, certifications and services by Sun Valley Health doctors. "Our Sun Valley Franchising team has toured the U.S. over the past six months sharing our Scientific Approach to Alternative Medicine," said Dustin Klein, SVP Business Development and Director. The Company is also pleased to announce that Andrejs Bunkse, a Company Director, will be participating as an expert panelist in the "Growing Your Business in the Cannabis Industry" - Fireside Chat hosted by Rebel Rock Accounting of Phoenix Arizona.
"January patient volumes were strong, setting the stage for potentially record first quarter patient visits, that are always focused on the patient experience, it's a competitive advantage and I continue to be impressed with how our team members care for each and every patient they see." said Steven McAuley, Chairman & CEO of Empower. The Company utilizes it's technology platform to communicate with patients by text message, email and call center ensuring appointments are confirmed and expected patient visits take place as planned. The Company's Sun Valley Health division also completed the set up and build out of it's retail product counter and sales areas in it's Tucson, AZ location, to showcase it's CBD product line with over 50 unique SKU's. Patients and customers can purchase product in clinic locations or online at www.sunvalleyhealth.com.
The first Sun Valley Health Franchise territory has been sold in Tulsa, Oklahoma, to a highly skilled entrepreneurial couple, with an extensive professional background that includes 20 years of owning and operating a health & wellness center. "The Sun Valley Health team have developed a robust pipeline of strong franchise candidates in multiple states across the U.S., who are all advocates of the medical cannabis clinic model." said Steven McAuley, Chairman & CEO of Empower. The state of Oklahoma is a medical cannabis state that has gone from non-existent to one of the largest and most valuable cannabis markets in the nation.
The Company had consistently strong patient traffic in each of the months of October, November and December 2019 versus the same periods in 2018 with 367%, 304% and 397% monthly year-over-year growth respectively. "I continue to be impressed with the operational excellence our team members provide to patients, who are returning to our clinics in record numbers." said Steven McAuley, Chairman & CEO of Empower. The Company today announced that it has granted, effective January 22, 2020, an aggregate of 870,000 stock options (each, an "Option") to certain employees and contractors of the Company in accordance with the Company's stock option plan.
VANCOUVER, BC / ACCESSWIRE / December 19, 2019 / Endocanna Health Inc. (" Endocanna "), a research and development biotechnology company specializing in endocannabinioid DNA testing, and a partly ...